Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has scheduled the release of its full year and fourth quarter 2024 financial results for Monday, March 10, 2025, before U.S. financial markets open. The commercial stage specialty pharmaceutical company will follow the release with a management-hosted conference call and webcast to discuss financial and business results.
Interested parties can access the live webcast through the company's website at www.fennecpharma.com under the Investors & Media section's News & Events/Event Calendar page. Participants are advised to connect at least 15 minutes before the conference call to allow time for any necessary software downloads. A replay of the webcast will be available on the company's website for thirty days following the event.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) ha programmato la pubblicazione dei suoi risultati finanziari per l'intero anno e il quarto trimestre 2024 per lunedì 10 marzo 2025, prima dell'apertura dei mercati finanziari statunitensi. L'azienda farmaceutica specializzata in fase commerciale seguirà la pubblicazione con una conferenza telefonica e un webcast ospitati dalla direzione per discutere i risultati finanziari e aziendali.
Le parti interessate possono accedere al webcast dal vivo attraverso il sito web dell'azienda all'indirizzo www.fennecpharma.com nella sezione Investitori & Media, pagina Notizie & Eventi/Calendario Eventi. Si consiglia ai partecipanti di collegarsi almeno 15 minuti prima della conferenza telefonica per consentire il tempo necessario per eventuali download software. Una registrazione del webcast sarà disponibile sul sito web dell'azienda per trenta giorni dopo l'evento.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) ha programado la publicación de sus resultados financieros del año completo y del cuarto trimestre 2024 para el lunes 10 de marzo de 2025, antes de la apertura de los mercados financieros de EE. UU. La compañía farmacéutica especializada en etapa comercial seguirá la publicación con una conferencia telefónica y un webcast organizados por la dirección para discutir los resultados financieros y comerciales.
Las partes interesadas pueden acceder al webcast en vivo a través del sitio web de la empresa en www.fennecpharma.com en la sección de Inversores y Medios, página de Noticias y Eventos/Calendario de Eventos. Se aconseja a los participantes conectarse al menos 15 minutos antes de la conferencia telefónica para permitir tiempo para cualquier descarga de software necesaria. Se dispondrá de una grabación del webcast en el sitio web de la empresa durante treinta días después del evento.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX)는 2024년 전체 연도 및 4분기 재무 결과 발표를 2025년 3월 10일 월요일에 미국 금융 시장 개장 전에 예정하고 있습니다. 상업 단계의 전문 제약 회사는 재무 및 사업 결과를 논의하기 위해 경영진 주최의 컨퍼런스 콜 및 웹캐스트를 진행할 것입니다.
관심 있는 분들은 회사 웹사이트 www.fennecpharma.com의 투자자 및 미디어 섹션의 뉴스 및 이벤트/이벤트 캘린더 페이지를 통해 실시간 웹캐스트에 접속할 수 있습니다. 참가자는 필요한 소프트웨어 다운로드 시간을 허용하기 위해 컨퍼런스 콜 시작 최소 15분 전에 연결하는 것이 좋습니다. 이벤트 후 30일 동안 회사 웹사이트에서 웹캐스트 재생을 이용할 수 있습니다.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) a programmé la publication de ses résultats financiers pour l'année entière et le quatrième trimestre 2024 pour le lundi 10 mars 2025, avant l'ouverture des marchés financiers américains. L'entreprise pharmaceutique spécialisée en phase commerciale suivra la publication avec une conférence téléphonique et un webcast animés par la direction pour discuter des résultats financiers et commerciaux.
Les parties intéressées peuvent accéder au webcast en direct via le site web de l'entreprise à www.fennecpharma.com dans la section Investisseurs & Médias, page Actualités & Événements/Calendrier des événements. Les participants sont invités à se connecter au moins 15 minutes avant la conférence téléphonique pour permettre le temps nécessaire pour tout téléchargement de logiciel. Un enregistrement du webcast sera disponible sur le site web de l'entreprise pendant trente jours suivant l'événement.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) hat die Veröffentlichung seiner Jahres- und vierten Quartalsfinanzergebnisse 2024 für Montag, den 10. März 2025, vor der Eröffnung der US-Finanzmärkte angesetzt. Das auf Spezialpharmazeutika in der kommerziellen Phase spezialisierte Unternehmen wird die Veröffentlichung mit einer von der Geschäftsführung veranstalteten Telefonkonferenz und einem Webcast folgen, um die finanziellen und geschäftlichen Ergebnisse zu besprechen.
Interessierte Parteien können über die Unternehmenswebsite www.fennecpharma.com im Bereich Investoren & Medien, Seite Nachrichten & Veranstaltungen/Veranstaltungskalender, auf den Live-Webcast zugreifen. Es wird empfohlen, dass Teilnehmer sich mindestens 15 Minuten vor der Telefonkonferenz einwählen, um Zeit für erforderliche Software-Downloads zu haben. Eine Aufzeichnung des Webcasts wird für dreißig Tage nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2024 financial results before the opening of the U.S. financial markets on Monday, March 10, 2025. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
Conference Call & Webcast Detail:
| Date: | Monday, March 10, 2025 |
| Time: | 8:30 a.m. Eastern Time |
| Link: | https://edge.media-server.com/mmc/p/7bafbd7q |
To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When will Fennec Pharmaceuticals (FENC) release Q4 2024 earnings?
How can investors access Fennec Pharmaceuticals' (FENC) Q4 2024 earnings call?
How long will FENC's Q4 2024 earnings call replay be available?
What time should investors join FENC's Q4 2024 earnings call?
